Clinical Trial Search

Primary: Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12 — -20.07; -41.46; -61.24; -60.46 percentage change — p=0.0027

Primary: Adverse Events in Terms of Dose-limiting Toxicity (DLT) and MTD of Bendamustine Hydrochloride (Phase I) — 0; 0; 0; 0 number of patients

Primary: Efficacy - 4 Weeks of Continuous Abstinence From Smoking Cigarettes — 14; 14; 32; 36 Participants

Primary: Change From MRX Baseline to Week 48 in Fasting sBA Levels — 261.96; 128.32 μmol/L — p=0.0012

Primary: Primary Safety Outcome Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading…

Primary: Progression-free Survival (PFS) — 5.1; 17.1; 11.9 percentage change of PSA

Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305

Primary: Objective Response Rate (ORR) — 35.2; 51.9 Percentage of participants

Primary: Patients Achieving Less Than or Equal to "2" RTOG Score At Visit 9 — 7 Participants

Primary: Percentage of Participants Achieving At Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16 — 11.8; 24.6; 21.7 percentage of…

Primary: Change in Glomerular Filtration Rate — -5; 1.00 ml/min/1.73 m2 — p=0.26

Primary: Percentage of Participants Achieving Erythroid Response (Week 13 to Week 24) — 77.1; 0.0 Percent of Participants

Primary: Autoantibodies to Human Epidermoid (HEp)-2 Cells — 288; 177 titer

Primary: Comparison of Sustained Viral Response at 12 Weeks Post Treatment (SVR12) in the Three Treatment Groups. — 3; 5; 3; 30 Participants — p=0.67

Primary: Systemic Tumor Response Rates (Complete Response+Partial Response) — .25; .083; 0 proportion of tumors